Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics ; volume:22 ; number:1 ; day:10 ; month:1 ; year:2024 ; pages:1-9 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (10.1.2024), 1-9, 12.2024
- Urheber
-
Yolchuyeva, Sevinj
Ebrahimpour, Leyla
Tonneau, Marion
Lamaze, Fabien
Orain, Michele
Coulombe, François
Malo, Julie
Belkaid, Wiam
Routy, Bertrand
Joubert, Philippe
Manem, Venkata SK
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-04854-z
- URN
-
urn:nbn:de:101:1-2024032510550933868591
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yolchuyeva, Sevinj
- Ebrahimpour, Leyla
- Tonneau, Marion
- Lamaze, Fabien
- Orain, Michele
- Coulombe, François
- Malo, Julie
- Belkaid, Wiam
- Routy, Bertrand
- Joubert, Philippe
- Manem, Venkata SK
- SpringerLink (Online service)
Ähnliche Objekte (12)
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study
Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line
Multi-institutional validation of a radiomics signature for identification of postoperative progression of soft tissue sarcoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study
Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line
Multi-institutional validation of a radiomics signature for identification of postoperative progression of soft tissue sarcoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study
Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line
Multi-institutional validation of a radiomics signature for identification of postoperative progression of soft tissue sarcoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment